News
Moderna announced Tuesday its RSV vaccine for older adults was about 84% effective at preventing severe disease and the company plans to ask the FDA for approval in 2023. ABC News.
The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna shares were up 5.9% on Wednesday, while Pfizer was up 1%. GSK’s American ...
And while 2023 brought the development of a monoclonal antibody for infants, a type of passive immunization that provides short-term protection from RSV, there has yet to be an actual RSV vaccine for ...
Moderna Inc.’s vaccine against RSV was highly effective in preventing the lung disease in older people, paving the way for the company to seek its first approval outside Covid-19.
According to a press release, Moderna’s RSV vaccine was 83.7% effective in preventing at least two symptoms associated with RSV in older adults (age 60 and up) in a phase-three clinical trial.
Moderna has submitted its RSV vaccine for people 60 and older regulatory approval in the United States, European Union, Switzerland and Australia.
Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA vaccine among them. It’s the company’s second product to ...
Moderna announced positive results Tuesday from its phase 3 trial of an RSV vaccine for older adults, revealing plans to submit the vaccine for regulatory approval, which includes review by the US ...
The Moderna RSV vaccine, which will be marketed under the name mResvia, was approved for adults 60 and older. It is made using the same messenger RNA platform as Moderna’s other licensed product ...
In doing so, Moderna would join Pfizer, which submitted a request for expedited review of its RSV vaccine for older adults last December. The company reported results similar to Moderna’s—it ...
Moderna said its Phase 3 trial enrolled about 37,000 people ages 60 and older in 22 countries including the U.S. About half were given a single dose of the RSV vaccine and the other half received ...
Moderna Inc.’s vaccine against RSV was highly effective in preventing the lung disease in older people, paving the way for the company to seek its first approval outside COVID-19.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results